{"id":"W2102177981","doi":"10.1177/1753465812470018","title":"Indacaterol 75 µg once daily for the treatment of patients with chronic obstructive pulmonary disease: a North American perspective","year":2013,"lang":"en","type":"review","venue":"Therapeutic Advances in Respiratory Disease","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Public Health Agency of Canada; Novartis Pharmaceuticals Corporation; AstraZeneca","keywords":"Indacaterol; Medicine; COPD; Tolerability; Placebo; Bronchodilator; Salmeterol; Internal medicine; Confidence interval; Minimal clinically important difference; Adverse effect; Randomized controlled trial; Anesthesia; Asthma","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00012218,0.001180636,0.002414954,0.0004761767,0.0002369717,0.00003864045,0.0007040965,0.0001051776,0.0001030599],"category_scores_gemma":[0.00008944981,0.0007089086,0.0008729331,0.001185634,0.002124883,0.0003996838,0.0001102422,0.0004962229,0.00002249756],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.004889428,"about_ca_system_score_gemma":0.003176419,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004815772,"about_ca_topic_score_gemma":0.00005487253,"domain_scores_codex":[0.9948875,0.0004761845,0.001065433,0.001493329,0.00105678,0.001020756],"domain_scores_gemma":[0.9948133,0.00084181,0.001057493,0.001758139,0.0006458276,0.0008834813],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.003169167,0.002146753,0.07522267,0.01019691,0.0007898051,0.0001111539,0.0001511946,0.00007967471,1.335431e-7,0.00008269279,0.000003596415,0.9080462],"study_design_scores_gemma":[0.002695866,0.001333852,0.4164391,0.002348838,0.003626573,0.000001536024,0.0002875924,0.00008937396,4.851081e-7,0.0001386909,0.5723656,0.0006725853],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.01138906,0.9728122,0.00007493169,0.00004308387,0.0001396685,0.01297156,0.002459498,0.00005809178,0.00005186407],"genre_scores_gemma":[0.0248316,0.9645878,0.00005241626,0.0001198302,0.0004223712,0.009124323,0.0004523229,0.000256056,0.0001532906],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9073737,"threshold_uncertainty_score":0.9995362,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03516204505204169,"score_gpt":0.3586399126017456,"score_spread":0.3234778675497039,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}